Research programme: NAV gene therapies - REGENXBIO

Drug Profile

Research programme: NAV gene therapies - REGENXBIO

Alternative Names: NAV® therapeutics - REGENXBIO; RGX 111; RGX-121; RGX-321

Latest Information Update: 17 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ReGenX Biosciences
  • Developer REGENXBIO; University of Pennsylvania Medical Center
  • Class Gene therapies; Proteins
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperlipoproteinaemia type IIa; Mucopolysaccharidosis I; Mucopolysaccharidosis II
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Mucopolysaccharidosis I; Mucopolysaccharidosis II; Retinitis pigmentosa
  • No development reported Age-related macular degeneration; Alzheimer's disease; Amyotrophic lateral sclerosis; Gaucher's disease; Leber congenital amaurosis; Mucopolysaccharidosis VI; Parkinson's disease

Most Recent Events

  • 15 Mar 2017 REGENXBIO has patents pending for RGX 111 and RGX 121 in USA (REGENXBIO, 10-K, March 2017)
  • 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
  • 13 Sep 2016 Pharmacodynamics data from a preclinical study of RGX 111 in Mucopolysaccharidosis-I released by REGENXBIO
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top